CORONA Remedies to Meet Investors on June 4-5
CORONA Remedies Limited will participate in a Non-Deal Roadshow (NDR) to meet investors. The meetings, organized by JM Financial, are scheduled for June 04-05, 2026, in Mumbai. Discussions will be limited to publicly available information.
This is a standard investor relations activity (Non-Deal Roadshow) and does not involve any new material information or strategic decisions that would significantly impact the company's stock or operations.
The announcement is a routine intimation about investor meetings and does not contain any new financial information or significant business updates that would sway the sentiment.
CORONA Remedies Limited announced its participation in a Non-Deal Roadshow (NDR) to meet investors. The meetings are scheduled for June 04, 2026, and June 05, 2026, starting from 09:00 A.M. IST onwards.
These 1x1 meetings will be organized by JM Financial and will take place in Mumbai. The discussions will be based solely on publicly available information, and no unpublished price sensitive information (UPSI) will be shared.
The company noted that the schedule may be subject to change due to unforeseen circumstances. This intimation is also available on the company's website.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.